Perrigo pharma has announced (in a press release Here) that patent litigation w.r.t Desloratadine tablets (5 mg) has been settled with innovator Schering. Perrigo has got license from innovator for this product. Earlier, innovator Schering sued Perrigo for patent infringement of US6100274 (which covers Stable formulation), US7214683 (which covers formulation of descarboethoxyloratadine) and US7214684 (method of use of descarboethoxyloratadine) based upon its filing of an ANDA containing a Paragraph IV certification. Under the terms of the settlement, Perrigo can commercially launch its generic Desloratadine product on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Perrigo product is awaiting USFDA approval.
Earlier, innovator had sued various generic players like Zydus, Sandoz, Mylan, Orchid, Perrigo, Glenmark, GeoPharma, Lupin, Ranbaxy, Sun, Watson, Dr. Reddy's who filed ANDA to market this product.
Earlier news of Ippharmadoc on this product Here
No comments:
Post a Comment